Details for Patent: 3,641,152

Summary for Patent: 3,641,152

Title:	3 4-dihydronaphthalenoneoxy-2-hydroxy-propylamines
Abstract:	THE PRESENT INVENTION RELATES TO COMPOUNDS OF THE FORMULA: 1-(O=),2-R5,2-R6,(R1-N(-R2)-CH2-CH(-OH)-CH2-O-),R3,R4- TETRALIN WHEREIN R1 STANDS FOR HYDROGEN OR AN ALKYL GROUP AND R2 STANDS FOR AN ALKYL GROUP OF NOT MORE THAN 6 CARBON ATOMS, PREFERABLY BRANCHED SUCH AS ISOPROPYL, ISOBUTYL, SEC-BUTYL, TERT-BUTYL, AND THE LIKE; CYCLOALKYL GROUPS OF NOT MORE THAN 7 CARBON ATOMS, SUCH AS CYCLOPROPYL, CYCLOPROPYLMETHYL, CYCLOPENTYL, CYCLOPENTYLMETHYL, CYCLOHEXYL, CYCLOHEXYLMETHYL; LWER ALKENYL OR ARALKYL GROUPS, ANY OF WHICH MAY BE OPTIONALLY SUBSTITUTED; R3 AND R4 EACH STAND FOR HYDROGEN, OR HYDROXY; R5 AND R6 EACH STAND FOR HYDROGEN, ALKYL, OR ARALKYL; OR7 IN WHICH R7 IS LOWER ALKYL OR LOWER ALKENYL, ARALKYL SUCH AS BENZYL IN WHICH ARYL MAY BE OPTIONALLY SUBSTITUTED BY HALOGEN, NITRO, ETC.; HALOGENS SUCH AS F,CL,BR OR I; NITRO, AMINO OR ACYLAMINO, OR SULFONAMIDO; ALKYL SUCH AS METHYL AND CONTAINING NOT MORE THAN 6 CARBONS.
Inventor(s):	John Shavel Jr, Sheldon Farber
Assignee:	Warner Lambert Co LLC
Application Number:	US761857A
Patent Claim Types: see list of patent claims

United States Patent 3,641,152: Scope, Claims, and Landscape

What does US 3,641,152 claim?

Insufficient information is available to produce a complete and accurate scope-and-claims analysis for United States Patent 3,641,152 because the claim text was not provided (“The claims are:” is present, but the claims themselves are missing).

No patent-claim construction, element-by-element mapping, or freedom-to-operate (FTO) implications can be stated without the actual claim language.

What is the patent landscape around US 3,641,152?

No landscape analysis can be produced to the required standard without being able to identify:

• the patent’s title/assignee and invention field,
• the inventors’ credited subject matter,
• the full claim set and claim dependencies,
• expiration status and exclusivity posture (including PTA/PTE if applicable),
• citation and family members (continuations/divisionals) and their claim scopes.

Without those inputs, any listing of competing filings, generic-entry timing, or “blocking” patents would risk being inaccurate.

---

Key Takeaways

• A scope and claims analysis for US 3,641,152 cannot be completed because the claim text is not included.
• A defensible patent landscape requires bibliographic and claim-level identifiers for the specific patent record.
• No high-stakes R&D or investment conclusions should be derived from an incomplete record.

FAQs

1. Can I get an element-by-element claim chart for US 3,641,152 without the claim text?
   No. Claim construction depends on the exact wording and dependencies.

2. Can you map US 3,641,152 to likely competitor products without knowing the invention field?
   No. Product mapping requires the patent’s subject matter and claim limitations.

3. Can you assess generic entry timing without knowing the patent’s expiration/exclusivity status?
   No. Timing depends on the grant, term adjustments, and any relevant exclusivity.

4. Can you list family members and continuations/divisionals without bibliographic data?
   No. Family and procedural history require the patent record.

5. Can you identify blocking patents or substitutes without claim scope?
   No. Blocking determinations are claim-specific.

---

References

[1] No sources were cited because no claim text or bibliographic identifiers for US 3,641,152 were provided.

Drugs Protected by US Patent 3,641,152

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 3,641,152

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Belgium	739195
Canada	957381
Switzerland	525183
Germany	1948144